DEMECAN enters into a Medical Cannabis Supply Agreement with MediPharm Labs Australia
Berlin/Dresden, 01. February 2021 – DEMECAN enters into a Supply-Agreement with MediPharm Labs Australia (MediPharm Labs) for the supply of multiple proprietary full-spectrum cannabis extracts. Under the agreement MediPharm Labs will supply DEMECAN over the next three years – with the option to extend the term of the agreement – an annual volume of at least 9,000 units of white-label cannabis extracts. Delivery is expected to commence in 2021, subject to regulatory and permitting requirements.
DEMECAN’s mission is the nationwide supply of high-quality medicinal cannabis for the benefit of patients in Germany. DEMECAN is the only independent German company that is mandated to cultivate and process medicinal cannabis nationally on behalf of the Federal Institute for Drugs and Medical Devices (BfArM). Furthermore, as a pharmaceutical wholesaler, DEMECAN cooperates with a selected number of international GMP-certified producers to guarantee a reliable and continuous supply of medical cannabis products for German patients. MediPharm Labs produces according to the same high pharmaceutical standards as DEMECAN. “As a global market leader and innovator in the production and supply of GMP certified cannabis extracts, we are excited to add DEMECAN to our international portfolio and work together to bring pharmaceutical quality products patients in Europe can trust”, said Warren Everitt, CEO, Asia Pacific, MediPharm Labs.
German physicians are permitted since 2017 to prescribe cannabis-based drugs to patients, including cannabis flowers and extracts. Full-spectrum cannabis extracts maintain the entire profile of active ingredients of the cannabis plant and are characterized by a simple oral administration and allow exact dosing. DEMECAN’s product portfolio offers the whole spectrum of combinations of THC and CBD, the two main active ingredients of cannabis, including product formulations with a high THC content, high CBD content and balanced proportions of THC and CBD. “We are excited to include MediPharm Labs in our international network of experienced suppliers, and offer physicians and patients a range of customized full-spectrum cannabis extracts in a timely manner”, said Dr. Cornelius Maurer, Managing Director and co-founder of DEMECAN.
DEMECAN is the only independent German company that covers the entire production chain for medical cannabis – from cultivation, processing, and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis with “Made in Germany” quality. The Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN the contract to grow and process medical cannabis in May 2019. Cultivation and further processing are carried out in accordance with the highest pharmaceutical standards at the facility near Dresden. As a pharmaceutical wholesaler, DEMECAN cooperates with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Cannabis Supplying Pharmacies (VCA e.V.).
Further Information: www.demecan.de
Press contact: firstname.lastname@example.org